Tumor ablation destroys cancerous tissue without removing it surgically. It suits patients with a small number of tumors, and at times patients who cannot undergo surgery. Many procedures are done on an outpatient basis, which is helping hospitals and patients adopt these systems quickly.
Tumor Ablation Market Overview
Tumor ablation has moved from a niche option to a core part of modern oncology. The procedure destroys tumors in place using heat, cold, or other energy sources, without open surgery. That makes it attractive for patients with a few small tumors and for those who are not good surgical candidates. Because it is minimally invasive and often done on an outpatient basis, it lowers infection risk, shortens hospital stays, and cuts costs for providers. These advantages, together with rising cancer incidence, an aging global population, and steady device innovation, are pushing the market onto a steep growth path. North America remains the largest regional market because of strong reimbursement and high cancer prevalence. Asia Pacific is expected to be the fastest-growing region as healthcare infrastructure improves and demand rises in Japan, China, and India.
Key numbers at a glance:
- Market size in 2025: USD 2.1 billion
- Estimated market size in 2026: USD 2.4 billion
- Projected market size by 2033: USD 6.1 billion
- Forecast CAGR (2026–2033): 14.1%
- North America's revenue share in 2025: 42.4%
- Radiofrequency ablation's share in 2025: 32.9%, the largest technology segment
- Microwave ablation's forecast CAGR: 14.9%, the fastest-growing technology segment
Market Dynamics: What's Driving Growth
Rising cancer burden. Higher prevalence of breast, colon, prostate and lung cancers is increasing demand for ablation in the liver, kidney, bone and soft tissue. The report cites an estimate of roughly 1.96 million new cancer cases and about 610,000 cancer deaths in the U.S. in 2023.
An aging population. Growth in the elderly population, particularly in Japan, India and China, is a major driver in Asia Pacific. The WHO projects that one in six people worldwide will be 60 or older by 2030.
Preference for minimally invasive care. Ablation involves no large incision, carries a lower infection risk than open surgery, and shortens hospital stays. That reduces trauma for patients and costs for providers.
Continuous device innovation. Better accuracy, portability and cost-effectiveness are pushing manufacturers to launch new systems, and regulatory clearances keep the pipeline moving. Examples include Medtronic's FDA 510(k) clearance for OsteoCool 2.0 in March 2024 and Stryker's OptaBlate clearance in September 2022.
Strategic partnerships. Companies use collaborations and distribution deals to access new technologies and markets. Examples include Medtronic's October 2025 partnership with AI software firm Techsomed and AngioDynamics' distribution agreement with AddLife for the UK, Ireland and the Nordics.
Want to see the depth of data before you decide? Explore real market estimates, trend analyses and forecast tables in a free sample of the report. It is a quick way to judge how the data can support your investment, product, or market-entry decisions. Download Free Sample Report
Market Restraints: What Could Slow Adoption
Competing therapies. Surgical resection, radiation therapy, chemotherapy, immunotherapy and targeted drugs all compete with ablation. Surgery is often preferred for early-stage localized tumors because of its curative potential, while systemic therapies dominate in advanced or metastatic disease.
Evidence, reimbursement and familiarity gaps. Where long-term clinical evidence, payer support or physician experience with ablation is limited, adoption can lag behind these alternatives.
Cost barriers in price-sensitive markets. In India, for example, the medium-to-high cost of ablation procedures may limit growth.
Low awareness. In markets such as Saudi Arabia, limited awareness of ablation devices may restrict uptake despite rising cancer incidence.
Technological Modalities Shaping the Market
Radiofrequency ablation (RFA) was the largest segment in 2025, with a 32.9% share. It uses heat from high-frequency energy delivered through a needle guided by imaging. It is also used outside oncology, for example in outpatient pain management.
Microwave ablation (MWA) is the fastest-growing technology, at a 14.9% CAGR. Its advantages include consistent high temperatures, larger ablation volumes, shorter procedure times and less pain. Clinical evidence such as the COLLISION trial in colorectal liver metastases supports its growing acceptance.
Cryoablation uses cold to destroy tumor tissue. In the THERMAC breast cancer trial, it showed a 94% complete ablation rate, compared with 72% for microwave ablation in the same study.
Irreversible electroporation (IRE) and HIFU are newer modalities. IRE extends ablation to larger and more complex tumors, and HIFU offers a noninvasive focused-ultrasound approach.
Image guidance and navigation includes fusion imaging, 3D visualization and navigation software. These tools improve planning and let clinicians assess the ablation zone during treatment, especially in hard-to-reach areas of the liver, kidney and lung.
By treatment approach, percutaneous ablation led in 2025, while laparoscopic ablation is expected to grow fastest. By application, liver cancer led and lung cancer is the fastest-growing segment.
Have specific questions about your business case? Whether you are sizing a new opportunity, benchmarking against competitors, or evaluating a regional launch, our research team can help you interpret the findings. Speak directly with the report's analysts to discuss segment trends, regional outlooks, or how the data applies to your strategy. Speak to Analyst
Prominent Industry Competitors
The market is moderately concentrated, with Medtronic, Boston Scientific, Johnson & Johnson (Ethicon) and Bioventus (Misonix) holding significant shares. Competition centers on geographic expansion, partnerships, product launches and M&A. The leading companies profiled in the report are:
- Medtronic plc
- Boston Scientific Corporation
- Johnson & Johnson Services Inc. (Ethicon, Inc.)
- AngioDynamics
- Bioventus Inc. (Misonix Inc.)
- EDAP TMS
- Chongqing Haifu Medical Technology Co., Ltd.
- Mermaid Medical
- HealthTronics, Inc.
- H.S. Hospital Service S.p.A.
Recent moves show where the competition is heading. In June 2025, Medtronic received FDA 510(k) clearance for its Visualase V2 MRI-guided laser ablation system. Varian's IntelliBlate system, launched in Europe, integrates image-guided microwave ablation for soft tissue tumors.
The Outlook
Rising cancer incidence, aging populations and demand for less invasive care give the tumor ablation market strong momentum. Competition from established cancer therapies and gaps in evidence, reimbursement and awareness remain the main hurdles. Companies that combine energy-delivery innovation with imaging and AI guidance, and that expand into high-growth regions such as Asia Pacific, are best positioned to capture the opportunity.
Explore our dedicated business services:
Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.
U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today
No comments:
Post a Comment